ArticleFrontiers in medicine2025
Association between intravenous magnesium sulfate and mortality in patients with sepsis-associated liver injury: a retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated liver injury (SALI) is a significant risk factor for mortality in patients with sepsis. Magnesium, as an essential electrolyte, has a correlation with adverse outcomes in critical illness when deficient, yet the therapeutic efficacy of magnesium sulfate in SALI remains undetermined. This study was designed to evaluate the association between magnesium sulfate therapy and prognosis in SALI patients. Method: This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, with the primary endpoint being 30-day all-cause mortality.Propensity score matching (PSM) achieved covariate balance, Kaplan-Meier survival curves and Cox regression were employed to analyze the magnesium sulfate-mortality relationship in SALI patients. The study results were externally validated using the eICU 2.0 database. Result: The present study was conducted on 648 SALI patients. After PSM, the 30-day all-cause mortality rate was significantly reduced in the magnesium sulfate group versus the non-magnesium sulfate group (30.4% vs. 44.6%, Conclusion: The use of magnesium sulfate is associated with a reduction in all-cause mortality among SALI patients. Future research should consider individual patient variations to explore its true effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.